Researchers have identified fibroblast growth factor 13 (FGF13) as a critical molecule in preserving neuronal integrity within the inner ear, potentially delaying or halting hearing decline linked to aging. This discovery contributes to the growing field of longevity-focused pharmaceutical development, where companies like Roche and Chugai are increasingly investing. The findings open avenues for targeted interventions in auditory neuroprotection and age-related sensory disorders.